Clinical trials: System Safety
T2DM (Type 2 Diabetes Mellitus)
Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393
A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-393 0.5/100/1000 mg under fed condition
- Trial name
- NCT04706286
- Testing
- CKD-501, D759, D150, CKD-393 0.5/100/1000 mg
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Poliomyelitis
Clinical Trial of Novel OPV2 Vaccine
Though OPV is safe and effective, it can mutate and reacquire neurovirulence in rare circumstances. This can result in vaccine-associated paralytic polio and circulating vaccine-derived polioviruses.
- Trial name
- NCT04693286
- Testing
- novel oral polio type 2 vaccine (nOPV2)
- Where
- Bangladesh
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Type 2 Diabetes
Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393
Objective Evaluation of the pharmacokinetic properties and safety of CKD-393 0.25/50/750 mg oral administration in healthy adults under fed condition.
- Trial name
- NCT05113693
- Testing
- CKD-393, CKD-501, D759, H053
- Where
- South Korea
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Smoking Cessation
The ESTxENDS Trial- Electronic Nicotine Delivery Systems (ENDS/Vaporizer/E-cigarette) as an Aid for Smoking Cessation.
Cigarette smoking is the leading cause of preventable death in Switzerland and still more than a quarter of the Swiss population smokes cigarettes.
- Trial name
- ESTxENDS (NCT03589989)
- Testing
- ENDS (vaporizer/e-cig) and smoking cessation counseling, Smoking cessation counseling
- Where
- 5 sites in Switzerland
- Volunteers
- 1,246 people, healthy volunteers welcome
- Sponsor
- University of Bern
Cystic Fibrosis
A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants
This is a 5-part study of FDL176. Part 1 is a double blind, placebo-controlled, dose escalation study in healthy male participants. Part 2 is a single dose, open-label study in healthy male participants.
- Trial name
- NCT03173573
- Testing
- FDL176
- Where
- 3 sites in Australia
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Flatley Discovery Lab LLC
Immune Thrombocytopenic Purpura (ITP)
Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients
The purpose of this study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in healthy volunteers and immune thrombocytopenic…
- Trial name
- NCT03866577
- Testing
- Biological: M254, Intravenous immunoglobulin (IVIg)
- Where
- 28 sites in United States, Belgium and 5 more
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Momenta Pharmaceuticals, Inc.
Androgenetic Alopecia
24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness
The purpose of this study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia
- Trial name
- NCT01686295
- Testing
- iRestore Hair Rejuvenation System
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Freedom Laser Therapy, Inc.
Healthy, Hepatic Insufficiency
A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment
The purpose of this study is to measure how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function and in healthy…
- Trial name
- NCT07165002
- Testing
- LY3537031
- Where
- 3 sites in Hungary, New Zealand and 1 more
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Neuropathic Pain
Evaluation of an ATP-Containing Parenteral Vitamin B Complex in Patients With Symptomatic Diabetic Polyneuropathy
Epinosine B Forte ampoule is an intramuscular injectable supplement containing adenosine triphosphate (ATP), Cocarboxylase (vitamin B1 derivative), vitamin B12, and nicotinamide (vitamin B3).
- Trial name
- NCT07296354
- Testing
- adenosine triphosphate, Vitamin B Complex
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Egyptian International Pharmaceutical Industries Co
Cystic Fibrosis, Mucociliary Clearance
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers
The purpose of this study is to evaluate the safety and tolerability of escalating doses of GS-9411 in healthy male volunteers. GS-9411 is a sodium channel inhibitor, that may restore airway hydration and mucociliary clearance in…
- Conditions
- Cystic Fibrosis, Mucociliary Clearance, Airway Hydration
- Trial name
- NCT00951522
- Testing
- GS-9411
- Where
- Australia
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Pancreatic Cancer
A Multi-center Study on the Efficacy and Safety of AI-assisted Navigation System for Biliopancreatic EUS
Pancreatic cancer is one of the most lethal cancers. Survival rates vary largely depending on the stage at which it is diagnosed. EUS is considered one of the most sensitive modalities for pancreatic cancer detection.
- Trial name
- NCT04892329
- Testing
- Artificial intelligence assistant system
- Where
- 2 sites in China
- Volunteers
- 285 people, healthy volunteers welcome
- Sponsor
- Renmin Hospital of Wuhan University
Hepatitis B
A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects
This study is a randomized, double-blind, placebo-controlled Phase I clinical study of TQ-A3334 tablets in adult healthy subjects, and the trial is planned to enroll 60 healthy subjects.
- Trial name
- NCT06160895
- Testing
- TQ-A3334 tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pharmacokinetics, Cardiodynamic ECG
A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate
This is a Phase I, single-center, double blind, placebo-controlled, parallel-group, randomized trial designed to evaluate the PK, cardiodynamic ECG effects, safety, and tolerability of single oral doses of linaprazan glurate.
- Conditions
- Pharmacokinetics, Cardiodynamic ECG, Safety, and Tolerability, GERD
- Trial name
- NCT05469854
- Testing
- Linaprazan glurate
- Where
- Sweden
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Cinclus Pharma Holding AB
Chronic Subdural Hematoma
Mgt of Chronic Subdural Hematoma Using Dexamethasone
Chronic subdural hematoma (cSDH) is a collection of blood and its breakdown products in the subdural compartment. It is a condition frequently seen in any neurosurgical practice.
- Trial name
- NCT02938468
- Testing
- Dexamethasone, Any surgical intervention aim at treating chronic subdural hematoma
- Where
- Canada
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Systemic Lupus Erythematosus
A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects
This will be a randomized, parallel-group, open-label, single-dose study of belimumab in healthy subjects to estimate the relative bioavailability, tolerability and safety of a single dose of belimumab 200 milligram (mg) when…
- Trial name
- NCT01894360
- Testing
- Belimumab 200 mg/mL
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Colonic Neoplasms
Mailed FIT Outreach to Improve Colon Cancer Screening in the Safety-net System
Uptake of colorectal cancer (CRC) screening is suboptimal in the San Francisco Health Network and access to care may be limited so novel models of health care delivery are warranted.
- Trial name
- NCT02613260
- Testing
- FIT Outreach
- Where
- United States
- Volunteers
- 13,470 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Ulcerative Colitis (UC)
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis
A study to investigate the safety, tolerability, and pharmacokinetics (PK) of ONO-6414 orally in healthy adult participants and in patients with active ulcerative colitis (UC).
- Trial name
- NCT07749768
- Testing
- ONO-6414
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fasting Conditions in Healthy Adult Volunteers
The objective of this clinical study is to compare the pharmacokinetics and the safety between a fixed-dose combination administration of "BR3005" and co-administration of "BR3005-1" and "BR3005-2" under fasting conditions in…
- Trial name
- NCT06289920
- Testing
- BR3005, BR3005-1, BR3005-2
- Where
- South Korea
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (exposure of drug) and pharmacodynamics (effect of drug) of NNC 0148-0000-0362 as tablets in healthy…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01597713
- Testing
- NNC 0148-0000-0362, insulin glargine
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Meningitis, Meningococcal, Serogroup B
Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age
This study will assess the safety, tolerability and immunogenicity of bivalent rLP2086 vaccine in laboratory workers ≥18 to ≤65 years of age administered on a Month 0, 2, and 6 schedule.
- Trial name
- B1971042 (NCT01768117)
- Testing
- rLP2086
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Pfizer